Form CORRESP - Correspondence:
SEC Accession No. 0001193125-23-122153
Filing Date
2023-04-27
Accepted
2023-04-27 16:10:01
Documents
2

Document Format Files

Seq Description Document Type Size
1 filename1.htm CORRESP 4760
2 GRAPHIC g407595dsp1.jpg GRAPHIC 6704
  Complete submission text file 0001193125-23-122153.txt   15072
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: CORRESP
SIC: 2836 Biological Products, (No Diagnostic Substances)